Introduction
Canakinumab (CAN), a selective, human, antiinterleukin-1β monoclonal antibody, has been shown to be efficacious in the treatment of SJIA (Ruperto et al. N Engl J Med 2012) .
Objectives
To explore baseline demographics and clinical characteristics that are most predictive of response to CAN in CAN-naïve SJIA patients during the initial 12 weeks of therapy.
Methods
Data from 3 trials were pooled for this analysis. CANnaïve patients (pts; n=178) aged 2-19 years with active SJIA were enrolled and received sc CAN 4 mg/kg/month; Predictors of response (according to aACR* 30, 70, and Inactive Disease [ID]) at Days (D) 15, 29, 57 and 85 were explored using univariate and multivariate logistic regression analyses. The candidate predictors (categorical variables) of CAN-response considered were: Age group, Gender, Prior NSAIDS (no/yes), Prior MTX(no/yes), Steroids (0, >0 -≤0.4;> 0.4), Number of Active Joints (≤10, 11-≤20, >20) and Joints with Limitation of Motion (≤10, 11-≤20,>20), CRP (elevated/normal) at baseline and at D15. All candidate predictors with p<0.1 in univariate analyses were included in the multivariate analysis. *ACR response plus absence of fever.
Results
By week 2 there was substantial clinical benefit with 102 pts (57%) and 36 pts (20%) achieving aACR70 and ID, respectively; by week 12, 108 pts (61%) had aACR70 and 50 pts (28%) ID. The multivariate analysis indicated that normal CRP at D15 is the only predictor significant (all p < 0.05) for ID at all time-points (Table 1) .
Conclusion
This exploratory analysis suggests that CAN-naïve patients with normal CRP (i.e. ≤10 mg/l) at Day 15, lower baseline steroid doses, low number of active joints, no prior anti-TNF or prior NSAID use are those most likely to achieve inactive disease up to 12 weeks. 
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